Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2

Yu. Yu. Polyakov; E. A. Baryakh; E. N. Misyurina; E. I. Zhelnova; M. A. Mingalimov; S. A. Kardovskaya; M. Ya. Smolyarchuk; T. N. Tolstykh; T. S. Chudnova; D. D. Ivanova; O. L. Kochneva; D. V. Lebedev; A. U. Abueva; A. M. Chistov; E. N. Zotina; I. V. Samsonova; M. A. Lysenko

doi:10.17650/1818-8346-2024-19-2-101-108

Онкогематология (Apr 2024)

Persistence of a new coronavirus infection in a patient with primary central nervous system large B-cell lymphoma with assessment of the humoral immune response against SARS-CoV-2

Yu. Yu. Polyakov,
E. A. Baryakh,
E. N. Misyurina,
E. I. Zhelnova,
M. A. Mingalimov,
S. A. Kardovskaya,
M. Ya. Smolyarchuk,
T. N. Tolstykh,
T. S. Chudnova,
D. D. Ivanova,
O. L. Kochneva,
D. V. Lebedev,
A. U. Abueva,
A. M. Chistov,
E. N. Zotina,
I. V. Samsonova,
M. A. Lysenko

Affiliations

Yu. Yu. Polyakov: City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
E. A. Baryakh: City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
E. N. Misyurina: City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
E. I. Zhelnova: City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
M. A. Mingalimov: City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
S. A. Kardovskaya: City Clinical Hospital No. 52, Moscow Healthcare Department
M. Ya. Smolyarchuk: Medicine and Nuclear Technologies LLC
T. N. Tolstykh: City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
T. S. Chudnova: City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
D. D. Ivanova: City Clinical Hospital No. 52, Moscow Healthcare Department
O. L. Kochneva: City Clinical Hospital No. 52, Moscow Healthcare Department
D. V. Lebedev: City Clinical Hospital No. 52, Moscow Healthcare Department; Medical and Biological University of Innovation and Continuing Education, State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency
A. U. Abueva: City Clinical Hospital No. 52, Moscow Healthcare Department; Peoples’ Friendship University of Russia named after Patrice Lumumba
A. M. Chistov: N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
E. N. Zotina: City Clinical Hospital No. 52, Moscow Healthcare Department; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
I. V. Samsonova: City Clinical Hospital No. 52, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
M. A. Lysenko: City Clinical Hospital No. 52, Moscow Healthcare Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

DOI: https://doi.org/10.17650/1818-8346-2024-19-2-101-108
Journal volume & issue: Vol. 19, no. 2
pp. 101 – 108

Abstract

Read online

Treatment of immunocompromised patients with novel coronavirus infection (COVID-19) presents significant challenges. Currently, there are no unified approaches to the treatment of persistent COVID-19 in hematological malignancies. There is a need to develop recommendations for the management of such patients, chemotherapy protocols, as well as therapy for COVID-19 in case of SARS-CoV-2 virus persistence. Doctors are faced with cases of virus persistence, clinical manifestations during a long course of the infectious process and are not provided with methodological recommendations for patient supervision. As scientific data on the persistent COVID-19 course in patients with lymphoproliferative diseases accumulates, it is planned to create recommendations for the treatment of COVID-19 for patients in this group. This article describes a clinical case of persistent COVID-19 course in a comorbid patient with primary central nervous system large B-cell lymphoma during chemotherapy.

Published in Онкогематология

ISSN: 1818-8346 (Print); 2413-4023 (Online)
Publisher: ABV-press
Country of publisher: Russian Federation
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website: http://oncohematology.abvpress.ru/

About the journal

Abstract

Keywords